Table 3.
Summary of efficacy endpoints
| Endpoints | No. (%) | [95% CI] or (range) |
|---|---|---|
| Overall CR + CRi + PR | 16 (41) | [26%, 58%] |
| CR+CRi | 12 (31) | [17%, 48%] |
| Median duration of CR+CRi, wk | 20.5 | (3.8-273.3) |
| CR | 10 (26) | [13%, 42%] |
| Median duration of CR, wk | 27 | (4.1-273.3) |
| CRi | 2 (5) | — |
| PR in T-ALL patients* | 4 (10) | |
| CR + CRi + PR | 11 (42) | [23%, 63%] |
| CR+CRi | 8 (31) | [14%, 52%] |
| PR in T-LBL patients† | ||
| CR + CRi + PR | 5 (38) | [14%, 68%] |
| CR | 4 (31) | [9%, 61%] |
| DFS, median wks | 20 | (11-56) |
| DFS at 1 year | 7 (25) | [6%, 50%] |
| OS, median wks | 20 | (13-36) |
| Survival at 1 year | 7 (28) | [15%, 43%] |
CR indicates complete remission; CRi, incomplete remission; CR+CRi, complete remission with or without hematologic recovery, PR, partial remission; DFS, disease-free survival; OS, overall survival.
*
N = 26.
†
N = 13.